Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo Using Proteomics Technology for Bristol-Myers Squibb Rx Discovery

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemical proteomics firm Kinaxo Biotechnologies will be using its technologies to support Bristol-Myers Squibb's drug discovery programs.

Under a deal announced today, Kinaxo will apply its technologies to deconvolute molecular targets of compounds on which the drug company is currently performing drug discovery work. The research, Kinaxo said, will allow Bristol-Myers Squibb to make more informed decisions at different stages of the drug discovery process, such as selecting the best compounds for clinical development.

Terms of the deal were not disclosed.

In a statement, Jutta Fritz, head of business development for Kinaxo said the agreement is a "major milestone" as the company expands its business into the US.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.